OncoMatch/Clinical Trials/NCT06795009
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
Is NCT06795009 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Zanzalintinib and Paclitaxel for uterine cancer.
Treatment: Zanzalintinib · Paclitaxel — The purpose of this study is to determine the recommended Phase 2 dose of zanzalintinib when given in combination with paclitaxel in patients with recurrent high-grade uterine cancer. Other objectives include overall safety and tolerability as well as rates of response.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Cancer type
Endometrial Cancer
Biomarker criteria
Allowed: MMR deficient mismatch repair
Patients with dMMR or MSI-H tumors or targetable HER2 alterations are required to have received prior therapy with appropriate targeted agents
Allowed: MSH2 microsatellite instability-high
Patients with dMMR or MSI-H tumors or targetable HER2 alterations are required to have received prior therapy with appropriate targeted agents
Allowed: HER2 (ERBB2) targetable alteration
Patients with dMMR or MSI-H tumors or targetable HER2 alterations are required to have received prior therapy with appropriate targeted agents
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: platinum-based chemotherapy
Patients must have experienced either prior progression on a platinum-based therapy or intolerance to platinum
Must have received: targeted therapy
Patients with dMMR or MSI-H tumors or targetable HER2 alterations are required to have received prior therapy with appropriate targeted agents
Cannot have received: zanzalintinib (zanzalintinib)
Any prior treatment with zanzalintinib
Cannot have received: tyrosine kinase inhibitor
any prior treatment with any tyrosine kinase inhibitor (TKI)
Cannot have received: bevacizumab (bevacizumab)
any prior treatment with bevacizumab
Cannot have received: small molecule kinase inhibitor
Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment
Cannot have received: cytotoxic chemotherapy
Receipt of any other (non-study) cytotoxic chemotherapy, radiation, targeted treatment, or immunotherapy (including investigational) within 4 weeks prior of start of study treatment
Cannot have received: radiation therapy
Receipt of any other (non-study) cytotoxic chemotherapy, radiation, targeted treatment, or immunotherapy (including investigational) within 4 weeks prior of start of study treatment
Cannot have received: targeted therapy
Receipt of any other (non-study) cytotoxic chemotherapy, radiation, targeted treatment, or immunotherapy (including investigational) within 4 weeks prior of start of study treatment
Cannot have received: immunotherapy
Receipt of any other (non-study) cytotoxic chemotherapy, radiation, targeted treatment, or immunotherapy (including investigational) within 4 weeks prior of start of study treatment
Cannot have received: investigational agent
Receipt of any other investigational agents or has received an investigational agent within 4 weeks of start of study treatment
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1.5 K/cumm without G-CSF support within 2 weeks of screening. Platelets ≥ 100 K/cumm without transfusion within 2 weeks. Hemoglobin ≥ 9.0 g/dL without transfusion within 2 weeks.
Kidney function
Serum creatinine < 1.5 x ULN OR calculated or measured creatinine clearance ≥ 40 mL/min (using Cockcroft-Gault equation)
Liver function
Total bilirubin ≤ 1.5 x IULN (for subjects with Gilbert's disease ≤ 3 x ULN). ALT, AST, and ALP ≤ 3 x ULN. For subjects with documented bone metastasis ALP ≤ 5 x ULN.
Cardiac function
INR ≤ 1.5 x IULN, aPTT ≤ 1.2 x IULN, QTcF ≤ 480 ms within 14 days per ECG (average of 3 consecutive results)
Adequate bone marrow and organ function within 14 days prior to first dose of study treatment, as defined below: Absolute neutrophil count ≥ 1.5 K/cumm...QTcF ≤ 480 ms within 14 days per ECG
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, San Francisco · San Francisco, California
- Washington University School of Medicine · St Louis, Missouri
- University of New Mexico · Albuquerque, New Mexico
- University of Oklahoma · Oklahoma City, Oklahoma
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06795009 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior zanzalintinib, tyrosine kinase inhibitor, bevacizumab disqualifies patients from enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages